• Molecular NameTriflupromazine
  • SynonymNA
  • Weight352.424
  • Drugbank_IDDB00508
  • ACS_NO146-54-3
  • Show 3D model
  • LogP (experiment)5.19
  • LogP (predicted, AB/LogP v2.0)5.58
  • pkaN/A
  • LogD (pH=7, predicted)3.45
  • Solubility (experiment)0.00177 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.26
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds5
  • TPSA31.78
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antipsychotic medication of the phenothiazine class (brandname Vesprin). Among different effects of triflupromazine indication for use of this drug is severe emesis.
  • Absorption_valueN/A
  • Absorption (description)Absorption may be erratic and peak plasma concentrations show large interindividual differences.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding90.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A